News - SLM Corporate

02 Mar

Sale of InjuryNET to Maximus Inc (NYSE: MMS)

In M&A Advisory by SLM / March 2, 2020 / 0 Comments

SLM Corporate is pleased to announce that it has acted as corporate adviser to the shareholders of InjuryNET on the sale of the company to Maximus Inc.

Established in 1998, InjuryNET has built a national medical practitioner network which provides over 8,000 initial treatments and over 40,000 medical assessments per annum, making InjuryNET one of Australia’s leading specialist providers of work-based medical treatment and assessment services.  The company provides injury management, medical assessment, medical advisory and fitness for duty services to a blue chip client base comprising some of the country’s largest employers.

Maximus Inc. is a New York Stock Exchange-listed public company which provides business process services to government, health and human services agencies in the United States, Australia, Canada, Saudi Arabia and the United Kingdom.  Its local subsidiary, Max Solutions, provides employment, disability and training services across Australia.

SLM worked closely with Arnold Bloch Leibler who acted as legal advisers to the shareholders of InjuryNET.

For more information on this transaction, please contact:

Barry Lewin

Managing Director

Ph: 03 9244 9644 or 0419 032493

Email: barry.lewin@slmcorporate.com.au

 

14 Oct

SLM advises ASX-listed global biopharmaceutical company Clinuvel Pharmaceuticals Limited (ASX: CUV) on updated remuneration arrangements for key executives

In Announcements,General News by SLM / October 14, 2019 / 0 Comments

SLM Corporate is pleased to announce that it has acted as independent adviser to the Remuneration Committee of the Board of Clinuvel Pharmaceuticals Limited in relation to the reasonableness of a proposed grant of performance rights to the Managing Director, and new remuneration arrangements for the Managing Director and Chief Financial Officer.

The proposed remuneration packages aimed to incentivise Clinuvel’s senior executives for achieving long term objectives, while awarding part of their incentives in Clinuvel equity in order to align their objectives and performance fully with the interests of the company’s shareholders.

SLM undertook benchmarking of the proposed packages against local and international comparable peers to Clinuvel, and also considered the experience of the executives and their track record of value creation for Clinuvel.  SLM’s findings and opinion as to the reasonableness of the proposed packages were presented to the Clinuvel Board’s Remuneration Committee.

Clinuvel is an ASX-listed global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders.  The award of the proposed performance rights was conditional on the US Food and Drug Administration (“FDA”) approving Clinuvel’s lead drug, SCENESSE®, for distribution to EPP patients, to enter the US market.  This FDA approval was granted on 9th October 2019.

For further information on this matter please contact:

Barry Lewin

Managing Director

Ph: 03 9244 9644 or 0419 032493

Email: barry.lewin@slmcorporate.com.au

-->